Developer docs
API playgroundTry for free, no card

Search company profiles

Egetis Therapeutics

Full company profile

uuid0002c9w

Namestring
Egetis Therapeutics
Legal namestring
Egetis Therapeutics AB (publ)
Websiteurl
egetis.com
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Egetis Therapeutics AB (publ) is a Swedish public pharmaceutical company headquartered in Stockholm, founded in 2006 (originally as PledPharma AB) and listed on Nasdaq Stockholm under ticker EGTX. The company focuses on late-stage development and commercialization of treatments for serious rare diseases with significant unmet medical needs in the orphan drug segment, operating through a wholly owned subsidiary, Rare Thyroid Therapeutics International AB, acquired in November 2020. It commercializes via a focused in-house organization in Europe and North America, with strategic partnerships in the Rest of World.

The company has two lead assets: Emcitate (tiratricol), a triiodothyronine (T3) analogue approved by the European Commission in February 2025 as the first and only treatment for MCT8 deficiency (Allan-Herndon-Dudley syndrome), under FDA Priority Review with a PDUFA date of September 28, 2026, and commercially launched in Germany in May 2025; and Aladote (calmangafodipir), a first-in-class drug candidate in pivotal Phase IIb/III development for paracetamol/acetaminophen overdose, effective beyond the 8-hour NAC window. Both assets hold Orphan Drug Designation in the US and EU, and Emcitate additionally holds Rare Pediatric Disease Designation and Breakthrough Therapy Designation, with composition-of-matter patent protection anticipated to extend to 2045.

Egetis generates revenue through product sales (Emcitate post-EU approval and Named Patient Programs in 25+ countries), licensing fees, and royalties from strategic partners. Pricing is not publicly disclosed, but the revenue model targets ultra-rare disease patient populations via Managed Access Programs and a US Expanded Access Program. Headcount is reported at 11-50, the shareholder base is led by Frazier Life Sciences (16.65%) and other healthcare-specialist investors, and the company raised SEK 350 million (~USD 38 million) in April 2026 to fund US commercialization and potential indication expansion.

Short descriptiontext

Egetis Therapeutics is a Swedish public pharmaceutical company (Nasdaq Stockholm: EGTX) developing and commercializing late-stage orphan drugs for serious rare diseases, with lead product Emcitate (tiratricol) approved in the EU and under FDA review for MCT8 deficiency, and Aladote (calmangafodipir) in late-stage development for paracetamol overdose.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orphan drug development, rare disease therapeutics, thyroid hormone analogues, MCT8 deficiency treatment, paracetamol overdose antidote
Industry4 codes
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Orphan Drug Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product sales
TypeSubscription Recurring
Description

Revenue generated primarily through sales of own products after gaining market approval. Emcitate is approved in the EU (February 2025) and launched in Germany in May 2025. Named Patient sales are already occurring.

egetis.com
2Licensing fees and royalties
TypeLicensing Royalties
Description

Named Patient sales from Emcitate as well as license fees and royalties through strategic partnerships are the main sources of revenue. License fees are received when initiating partnerships or at defined milestones (non-recurring). Royalties are recurring revenue received when a drug is sold in the market.

egetis.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1Emcitate (tiratricol) for MCT8 deficiency
ModelOtherBilling cadenceOther
Notes

Pricing details are not publicly disclosed. The product is available through Managed Access Programs in more than 25 countries and a USA Expanded Access Program (EAP) initiated at FDA's request.

egetis.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Emcitate
Description

Lead investigational therapy for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome (AHDS). Approved in EU in February 2025.

egetis.com
+1 more record
Core offering1 text field

Egetis Therapeutics develops and commercializes proprietary orphan drug therapies for serious rare diseases. Its lead product Emcitate (tiratricol) is a T3 analogue approved in the EU for MCT8 deficiency (Allan-Herndon-Dudley syndrome) and under FDA Priority Review, and Aladote (calmangafodipir) is a first-in-class candidate to reduce acute liver injury from paracetamol overdose. Both target life-threatening conditions with no adequate existing treatments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Statistically and clinically significant reduction in serum T3 levels demonstrated in Triac Trial I (multinational Phase 2b study) and long-term real-life study of 67 patients over up to 6 years.
+1 more record
Product overview1 text field

Egetis Therapeutics is an innovative pharmaceutical company focused on late-stage development and commercialization of treatments for serious rare diseases with significant unmet medical needs in the orphan drug segment. The company has two lead products: Emcitate (tiratricol), approved in the EU for MCT8 deficiency and under FDA review for US approval, and Aladote (calmangafodipir), a first-in-class candidate for paracetamol overdose, currently in clinical development. Both products target rare diseases with no adequate treatments available.

Product and service2 records
1Emcitate (tiratricol)
CategoryOrphan drug / rare disease therapeutic
Description

Emcitate is a triiodothyronine (T3) analogue developed for the treatment of MCT8 deficiency (Allan-Herndon-Dudley syndrome), a rare X-linked genetic disorder. It restores thyroid hormone signaling in cells with defective MCT8 transporter and significantly reduces serum T3 levels. Approved in the EU (February 2025) and under FDA Priority Review with PDUFA target action date of September 28, 2026.

2Aladote (calmangafodipir)
CategoryOrphan drug / acute care therapeutic
Description

Aladote is a first-in-class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. Its mechanism is effective even in the time window beyond 8 hours post-ingestion when standard N-acetylcysteine (NAC) treatment is no longer effective. Granted Orphan Drug Designation in the U.S. and EU.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Led the multinational Phase 2b Triac Trial I and investigator-initiated long-term real-life study evaluating Emcitate in 67 patients over up to 6 years across 33 centers. Key academic collaborator providing clinical trial expertise.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Patient advocacy foundation working to improve quality of life for MCT8-AHDS patients, support families, raise awareness, and advance research. Collaborates with Egetis on awareness initiatives including the Behind the Mystery TV episode.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage biopharmaceutical company developing RNA interference therapeutics for rare genetic diseases. Comparable in addressing serious rare genetic conditions with novel mechanisms of action and global orphan drug commercialization strategies.

TypeDirect peer
Description

Late-stage rare disease biopharmaceutical company developing and commercializing treatments for serious rare and ultra-rare genetic diseases. Closely comparable business model with focus on first-in-class orphan therapies, regulatory exclusivity, and targeted specialty commercialization.

TypeDirect peer
Description

Commercial-stage rare disease company focused on serious liver and neurological diseases (Livmarli, Cholbam). Comparable in scale, late-stage orphan focus, and similar commercial strategy targeting ultra-rare patient populations. Egetis's newly appointed CMO previously led clinical development at Mirum.

TypeDirect peer
Description

Swedish specialty pharmaceutical company focused on rare diseases, headquartered in Stockholm. Comparable in domicile, size, and orphan drug focus (Tarpeyo for IgA nephropathy). Egetis's VP Technical Operations previously served as VP Operations at Calliditas.

TypeDirect peer
Description

Commercial-stage biopharmaceutical company developing precision genetic medicines for rare diseases. Comparable in addressing rare genetic disorders with high unmet need, premium orphan pricing, and focused commercial organization. Egetis's President of North America previously held a VP role at Sarepta.

TypeBroad incumbent
Description

Established global rare disease biopharmaceutical company with a broad portfolio across multiple rare disease franchises. Comparable orphan drug business model and patient access strategies, though significantly larger and more diversified than Egetis.

TypeBroad incumbent
Description

Swedish-based international rare disease biopharmaceutical company focused on rare diseases and specialty care. Comparable in domicile, regulatory pathway expertise, and European rare disease commercialization infrastructure, though Sobi operates at substantially larger scale.

TypeEmerging player
Description

Biopharmaceutical company focused on liver diseases with therapies addressing serious non-viral liver conditions. Comparable in liver-focused therapeutic development relevant to Egetis's Aladote program for paracetamol-induced acute liver injury.

TypeBroad incumbent
Description

Global specialty biopharmaceutical group with a strong rare disease franchise (including rare endocrine and metabolic disorders). Comparable in addressing rare endocrine conditions with limited patient populations and leveraging orphan drug regulatory pathways.

TypeBroad incumbent
Description

Specialty pharmaceutical division of Recordati focused on treatments for rare diseases. Comparable in commercial focus on orphan drug distribution, patient access programs, and partnership-based entry into ultra-rare disease markets globally.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Egetis Therapeutics

Orphan Drug Specialty Pharmaceuticalsegetis.com

Egetis Therapeutics is a Swedish public pharmaceutical company (Nasdaq Stockholm: EGTX) developing and commercializing late-stage orphan drugs for serious rare diseases, with lead product Emcitate (tiratricol) approved in the EU and under FDA review for MCT8 deficiency, and Aladote (calmangafodipir) in late-stage development for paracetamol overdose.

What Egetis Therapeutics does

Egetis Therapeutics AB (publ) is a Swedish public pharmaceutical company headquartered in Stockholm, founded in 2006 (originally as PledPharma AB) and listed on Nasdaq Stockholm under ticker EGTX. The company focuses on late-stage development and commercialization of treatments for serious rare diseases with significant unmet medical needs in the orphan drug segment, operating through a wholly owned subsidiary, Rare Thyroid Therapeutics International AB, acquired in November 2020. It commercializes via a focused in-house organization in Europe and North America, with strategic partnerships in the Rest of World.

The company has two lead assets: Emcitate (tiratricol), a triiodothyronine (T3) analogue approved by the European Commission in February 2025 as the first and only treatment for MCT8 deficiency (Allan-Herndon-Dudley syndrome), under FDA Priority Review with a PDUFA date of September 28, 2026, and commercially launched in Germany in May 2025; and Aladote (calmangafodipir), a first-in-class drug candidate in pivotal Phase IIb/III development for paracetamol/acetaminophen overdose, effective beyond the 8-hour NAC window. Both assets hold Orphan Drug Designation in the US and EU, and Emcitate additionally holds Rare Pediatric Disease Designation and Breakthrough Therapy Designation, with composition-of-matter patent protection anticipated to extend to 2045.

Egetis generates revenue through product sales (Emcitate post-EU approval and Named Patient Programs in 25+ countries), licensing fees, and royalties from strategic partners. Pricing is not publicly disclosed, but the revenue model targets ultra-rare disease patient populations via Managed Access Programs and a US Expanded Access Program. Headcount is reported at 11-50, the shareholder base is led by Frazier Life Sciences (16.65%) and other healthcare-specialist investors, and the company raised SEK 350 million (~USD 38 million) in April 2026 to fund US commercialization and potential indication expansion.

Egetis Therapeutics firmographics

Firmographics
Name
Egetis Therapeutics
Legal name
Egetis Therapeutics AB (publ)
Website
https://egetis.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
51–100 employees
Short description
Egetis Therapeutics is a Swedish public pharmaceutical company (Nasdaq Stockholm: EGTX) developing and commercializing late-stage orphan drugs for serious rare diseases, with lead product Emcitate (tiratricol) approved in the EU and under FDA review for MCT8 deficiency, and Aladote (calmangafodipir) in late-stage development for paracetamol overdose.
Ownership category
akta.pro rank

Egetis Therapeutics industry classification

Industry
Product category
Orphan Drug Specialty Pharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Orphan drug development
  • Rare disease therapeutics
  • Thyroid hormone analogues
  • MCT8 deficiency treatment
  • Paracetamol overdose antidote

Where Egetis Therapeutics is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Egetis Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Product sales: Revenue generated primarily through sales of own products after gaining market approval. Emcitate is approved in the EU (February 2025) and launched in Germany in May 2025. Named Patient sales are already occurring.
  2. Licensing fees and royalties: Named Patient sales from Emcitate as well as license fees and royalties through strategic partnerships are the main sources of revenue. License fees are received when initiating partnerships or at defined milestones (non-recurring). Royalties are recurring revenue received when a drug is sold in the market.

Pricing tiers

ModelBillingPrice
OtherOtherEmcitate (tiratricol) for MCT8 deficiency

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Egetis Therapeutics product offering

Product offering

Core offering

Egetis Therapeutics develops and commercializes proprietary orphan drug therapies for serious rare diseases. Its lead product Emcitate (tiratricol) is a T3 analogue approved in the EU for MCT8 deficiency (Allan-Herndon-Dudley syndrome) and under FDA Priority Review, and Aladote (calmangafodipir) is a first-in-class candidate to reduce acute liver injury from paracetamol overdose. Both target life-threatening conditions with no adequate existing treatments.

Product overview

Egetis Therapeutics is an innovative pharmaceutical company focused on late-stage development and commercialization of treatments for serious rare diseases with significant unmet medical needs in the orphan drug segment. The company has two lead products: Emcitate (tiratricol), approved in the EU for MCT8 deficiency and under FDA review for US approval, and Aladote (calmangafodipir), a first-in-class candidate for paracetamol overdose, currently in clinical development. Both products target rare diseases with no adequate treatments available.

Differentiator

Problem solved

Functional benefit

Brands

  • Emcitate: Lead investigational therapy for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome (AHDS). Approved in EU in February 2025.
  • Aladote

Products and services

  • Emcitate (tiratricol) Emcitate is a triiodothyronine (T3) analogue developed for the treatment of MCT8 deficiency (Allan-Herndon-Dudley syndrome), a rare X-linked genetic disorder. It restores thyroid hormone signaling in cells with defective MCT8 transporter and significantly reduces serum T3 levels. Approved in the EU (February 2025) and under FDA Priority Review with PDUFA target action date of September 28, 2026.
  • Aladote (calmangafodipir) Aladote is a first-in-class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. Its mechanism is effective even in the time window beyond 8 hours post-ingestion when standard N-acetylcysteine (NAC) treatment is no longer effective. Granted Orphan Drug Designation in the U.S. and EU.

Quantifiable outcome

  • Statistically and clinically significant reduction in serum T3 levels demonstrated in Triac Trial I (multinational Phase 2b study) and long-term real-life study of 67 patients over up to 6 years.
  • +1 more outcomes

Companies that use Egetis Therapeutics

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Egetis Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Egetis Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Erasmus University Medical CentercoreStrategic or Co-development PartnerLed the multinational Phase 2b Triac Trial I and investigator-initiated long-term real-life study evaluating Emcitate in 67 patients over up to 6 years across 33 centers. Key academic collaborator providing clinical trial expertise.
  • MCT8-AHDS FoundationcoreStrategic or Co-development PartnerPatient advocacy foundation working to improve quality of life for MCT8-AHDS patients, support families, raise awareness, and advance research. Collaborates with Egetis on awareness initiatives including the Behind the Mystery TV episode.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Egetis Therapeutics competitors and assessment

Company assessment

Direct peers

  • Alnylam Pharmaceuticals: Commercial-stage biopharmaceutical company developing RNA interference therapeutics for rare genetic diseases. Comparable in addressing serious rare genetic conditions with novel mechanisms of action and global orphan drug commercialization strategies.
  • Ultragenyx Pharmaceutical: Late-stage rare disease biopharmaceutical company developing and commercializing treatments for serious rare and ultra-rare genetic diseases. Closely comparable business model with focus on first-in-class orphan therapies, regulatory exclusivity, and targeted specialty commercialization.
  • Mirum Pharmaceuticals: Commercial-stage rare disease company focused on serious liver and neurological diseases (Livmarli, Cholbam). Comparable in scale, late-stage orphan focus, and similar commercial strategy targeting ultra-rare patient populations. Egetis's newly appointed CMO previously led clinical development at Mirum.
  • Calliditas Therapeutics: Swedish specialty pharmaceutical company focused on rare diseases, headquartered in Stockholm. Comparable in domicile, size, and orphan drug focus (Tarpeyo for IgA nephropathy). Egetis's VP Technical Operations previously served as VP Operations at Calliditas.
  • Sarepta Therapeutics: Commercial-stage biopharmaceutical company developing precision genetic medicines for rare diseases. Comparable in addressing rare genetic disorders with high unmet need, premium orphan pricing, and focused commercial organization. Egetis's President of North America previously held a VP role at Sarepta.

Broad incumbents

  • BioMarin Pharmaceutical: Established global rare disease biopharmaceutical company with a broad portfolio across multiple rare disease franchises. Comparable orphan drug business model and patient access strategies, though significantly larger and more diversified than Egetis.
  • Swedish Orphan Biovitrum (Sobi): Swedish-based international rare disease biopharmaceutical company focused on rare diseases and specialty care. Comparable in domicile, regulatory pathway expertise, and European rare disease commercialization infrastructure, though Sobi operates at substantially larger scale.
  • Ipsen: Global specialty biopharmaceutical group with a strong rare disease franchise (including rare endocrine and metabolic disorders). Comparable in addressing rare endocrine conditions with limited patient populations and leveraging orphan drug regulatory pathways.
  • Recordati Rare Diseases: Specialty pharmaceutical division of Recordati focused on treatments for rare diseases. Comparable in commercial focus on orphan drug distribution, patient access programs, and partnership-based entry into ultra-rare disease markets globally.

Emerging players

  • Intercept Pharmaceuticals: Biopharmaceutical company focused on liver diseases with therapies addressing serious non-viral liver conditions. Comparable in liver-focused therapeutic development relevant to Egetis's Aladote program for paracetamol-induced acute liver injury.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Egetis Therapeutics social profiles

Digital presence

Egetis Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Egetis Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Egetis Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Egetis Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Egetis Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Egetis Therapeutics

What does Egetis Therapeutics do?

Egetis Therapeutics develops and commercializes proprietary orphan drug therapies for serious rare diseases. Its lead product Emcitate (tiratricol) is a T3 analogue approved in the EU for MCT8 deficiency (Allan-Herndon-Dudley syndrome) and under FDA Priority Review, and Aladote (calmangafodipir) is a first-in-class candidate to reduce acute liver injury from paracetamol overdose. Both target life-threatening conditions with no adequate existing treatments.

Is Egetis Therapeutics a public or private company?

Egetis Therapeutics is a public company. It is classified as public and is currently operating.

When was Egetis Therapeutics founded?

Egetis Therapeutics was founded in 2006. It employs 51 to 100 people.

Where is Egetis Therapeutics based?

Egetis Therapeutics is headquartered in Stockholm, Sweden, in the Europe region.

How does Egetis Therapeutics make money?

Two revenue lines are on record. Product sales are the primary driver. The others are licensing fees and royalties.

Who are Egetis Therapeutics's main competitors?

Direct peers on record are Alnylam Pharmaceuticals, Ultragenyx Pharmaceutical, Mirum Pharmaceuticals, Calliditas Therapeutics and Sarepta Therapeutics. Broad incumbents are BioMarin Pharmaceutical, Swedish Orphan Biovitrum (Sobi), Ipsen and Recordati Rare Diseases. Intercept Pharmaceuticals is listed as an emerging player.

Does Egetis Therapeutics have an API?

No public API is recorded for Egetis Therapeutics.

What industry is Egetis Therapeutics in?

Egetis Therapeutics's product category is Orphan Drug Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies, with a secondary code of HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewANIP: Cortrophin demand accelerates as the Egetis offer expands rare-disease reachANIP's rare-disease segment now contributes over half of sales, with Cortrophin demand strong despite specialty pharmacy bottlenecks. The proposed Egetis acquisition adds Emcitate, which has $300M+ peak sales potential and is expected to cause year-one EPS dilution.TradingViewANIP: Strong Q3 growth and an Egetis offer offset by Cortrophin fulfillment delaysANI Pharmaceuticals reported Q3 2026 revenue growth of 28% year-over-year and adjusted EBITDA up 40%. The company cut its Cortrophin guidance due to fulfillment bottlenecks, while a proposed Egetis deal adding EMCITATE is expected to close in late 2026 or early 2027.The future of tradingEgetis Therapeutics AB (publ) receives observation statusANI Pharmaceuticals disclosed a public takeover offer to Egetis Therapeutics shareholders on November 5, 2026. Nasdaq Stockholm granted observation status to the company's shares under the rulebook provision for takeover offers. The notice provides no further details on the offer's terms.Dagens industriStorägaren spådde miljardbudet – nu accepterar hanPeter Lindell, a major shareholder and investor in Egetis Therapeutics, accepted a billion-dollar bid for the midcap drug developer after it received FDA approval. The bid, which he had predicted, was announced a month after the approval.Dagens industriStorägaren spådde miljardbudet – nu accepterar hanAni Pharmaceuticals made a $11.25-per-share cash bid on Egetis Therapeutics, which the board recommended shareholders accept. The bid, worth 5.5 billion kronor, includes a 12.6% premium, and Peter Lindell, a major shareholder, accepted it. The deal is conditional on over 90% acceptance.AffarsvarldenEgetis rusar på stigande börsEgetis Therapeutics stock rose 11.5% to 11.12 kronor after ANI Pharmaceuticals made a recommended cash offer worth about 5.3 billion kronor. The offer of 11.25 kronor per share represents a 12.6% premium to Wednesday's closing price. The broader market also saw gains, with the OMXS30 up 0.75%.Business & FinancialREPEAT ANI Pharmaceuticals Announces Offer To Acquire Egetis Therapeutics, Expanding The Scope And Scale Of Its Rare Disease BusinessANI Pharmaceuticals announced a recommended public offer to acquire Egetis Therapeutics for SEK 11.25 per share, a 27% premium to the 60-day VWAP, with a total value of approximately SEK 5.6 billion or $560 million. The deal includes Egetis' sale of its Rare Pediatric Disease Priority Review Voucher for $190 million, and ANI expects to release Q3 2026 results and host a conference call today.GlobeNewswireANI Pharmaceuticals Reports Third Quarter 2026 Financial ResultsANI Pharmaceuticals reported Q3 2026 net revenues of $290.8 million, up 27.6% year-over-year, with Cortrophin Gel revenue rising 36.1% to $138.7 million. The company narrowed its full-year revenue guidance to $1,085–$1,125 million and announced an offer to acquire Egetis Therapeutics for approximately $5.6 billion.citybizANI Pharmaceuticals Offers $560 Million to Acquire Egetis Therapeutics, Expand Rare Disease PortfolioANI Pharmaceuticals launched a recommended public offer to acquire Egetis Therapeutics for about $560 million, expanding its rare disease portfolio. The deal values Egetis at SEK 11.25 per share, a 27% premium, and includes EMCITATE, approved in Europe and the U.S. for a rare genetic disorder, with peak annual sales estimated above $300 million.FiercePharmaANI makes $560M play for Egetis and its approved orphan drug EmcitateANI Pharmaceuticals announced a $560 million offer to acquire Egetis Therapeutics, bringing its approved orphan drug Emcitate into its portfolio. Emcitate, the first treatment for MCT8 deficiency, could reach $300 million in peak sales. ANI expects full-year revenue of $1.1 billion.